Mounjaro vs Ozempic: Head-to-Head Clinical Comparison

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Both Mounjaro and Zepbound contain the same active ingredient, tirzepatide, and are given as weekly subcutaneous injections.
Mounjaro is FDA-approved for adults with type 2 diabetes, while Zepbound is approved for chronic weight management in adults with obesity or overweight with comorbidities, and for obstructive sleep apnea in adults with obesity.
In clinical trials, tirzepatide at a 15 mg dose led to an average weight loss of 20.9% of body weight over 72 weeks Zepbound vs. Mounjaro Comparison Guide.
Common side effects for both include nausea (12-22% of patients), diarrhea (12-16%), and vomiting (6-13%).

Mounjaro and Zepbound are two brand-name medications that share the exact same active ingredient: tirzepatide. This means they operate identically within the body, activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Despite this shared foundation, their primary distinction lies in their official FDA approvals. Mounjaro is specifically approved for improving blood sugar control in adults with type 2 diabetes, used alongside diet and exercise. Zepbound, on the other hand, is approved for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as high blood pressure, and also for moderate to severe obstructive sleep apnea in adults with obesity. Clinical trials have shown significant weight loss efficacy for tirzepatide, with patients achieving an average of 20.9% body weight reduction at a 15 mg dose over 72 weeks. We see that while these medications are chemically identical, their prescribed applications and insurance coverage pathways often diverge based on these specific approvals.

What are Mounjaro and Zepbound?

Mounjaro and Zepbound are both injectable prescription medications that utilize the active ingredient tirzepatide. This means they are, in essence, two different brand names for the same powerful drug. They are administered as a once-weekly subcutaneous injection, meaning the medicine is injected just under the skin. The core of their function comes from tirzepatide's unique ability to work on two specific gut hormone receptors in the body: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action is what sets tirzepatide apart from some other medications in the GLP-1 class, which only mimic the GLP-1 hormone. Dr. Eleanor Yusupov, D.O., an assistant professor at New York Institute of Technology’s medical school in Westbury, New York, explains this distinction clearly: "Zepbound is different from Ozempic and other GLP-1s. That’s because it [mimics] two gut hormones — GLP-1 and GIP — to control blood sugar, increase insulin, decrease glucagon (a hormone that raises blood sugar), slow down food leaving the stomach, and regulate appetite." This comprehensive approach helps the body manage blood sugar, control appetite, and ultimately supports weight loss.

The Science Behind Tirzepatide

Tirzepatide's mechanism of action is multifaceted and highly effective due to its dual agonism of GIP and GLP-1 receptors. Both GIP and GLP-1 are naturally occurring incretin hormones that play crucial roles in metabolic regulation. When these receptors are activated by tirzepatide, several beneficial physiological changes occur. One primary effect is the stimulation of insulin release, but only when blood glucose levels are elevated. This glucose-dependent action is important because it reduces the risk of hypoglycemia, or dangerously low blood sugar. This targeted insulin release helps to bring high blood sugar levels back into a healthy range, making it particularly beneficial for individuals with type 2 diabetes.

Another key function is the slowing of gastric emptying. This means that food stays in the stomach for a longer period. The result is a prolonged feeling of fullness, or satiety, which naturally leads to reduced food intake. This slower digestion also contributes to better control of post-meal sugar spikes, as glucose is absorbed into the bloodstream more gradually. Beyond insulin and gastric emptying, tirzepatide also works to reduce glucagon production from the liver. Glucagon is a hormone that typically raises blood sugar levels, so decreasing its production helps to further lower overall blood glucose. The medication also improves insulin sensitivity, meaning the body's cells become more responsive to the insulin that is produced, allowing glucose to be absorbed and utilized more effectively. Finally, tirzepatide influences the central nervous system to reduce appetite, directly contributing to decreased caloric intake and, consequently, weight loss. This comprehensive action on multiple metabolic pathways is what makes tirzepatide a powerful tool for both blood sugar management and chronic weight management. The efficacy and safety of tirzepatide have been extensively studied in people with obesity, demonstrating its novel approach to a chronic disease that causes significant global health issues NEJM Tirzepatide Obesity Study.

Shared Administration and Dosage

Both Zepbound and Mounjaro are administered in the same way: as a once-weekly subcutaneous injection. This ease of administration is a significant advantage for patients, as it eliminates the need for daily injections and simplifies adherence to the treatment regimen. The medication comes in pre-filled pens, designed for user-friendliness, allowing patients to administer their dose at home after proper training from a healthcare provider. The dosing strategy for tirzepatide typically involves starting with a lower dose and gradually increasing it over several weeks or months. This titration process helps the body adjust to the medication, minimizing potential side effects such as nausea and stomach upset. While the specific dosing protocols might differ slightly based on the medication's approved use (diabetes versus weight management), the active ingredient and the method of delivery remain consistent. This shared approach ensures that patients receiving either Zepbound or Mounjaro benefit from the same underlying pharmacology and a convenient weekly dosing schedule.

What are the FDA-Approved Uses for Each Medication?

The primary difference between Mounjaro and Zepbound, despite sharing the same active ingredient, lies in their specific FDA approvals. These approvals dictate which patient populations can be prescribed each medication and often influence insurance coverage. Mounjaro is primarily indicated for the treatment of type 2 diabetes in adults. It is used in conjunction with diet and exercise to help improve blood sugar control in these patients. Zepbound, on the other hand, has received FDA approval for chronic weight management in adults with obesity, defined as a Body Mass Index (BMI) of 30 kg/m² or greater. It is also approved for adults who are overweight, with a BMI of 27 kg/m² or greater, provided they have at least one weight-related condition such as high blood pressure, dyslipidemia (unhealthy cholesterol levels), or sleep apnea. In 2024, Zepbound expanded its indications to include the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, further solidifying its role in comprehensive weight-related health management.

Mounjaro: Focusing on Glycemic Control

Mounjaro's journey to FDA approval was centered on its ability to improve glycemic control in individuals with type 2 diabetes. This means its clinical trials specifically evaluated its effectiveness in lowering blood glucose levels, reducing HbA1c (a measure of average blood sugar over two to three months), and enhancing the body's natural insulin response. Dr. Andrew Shapiro, M.D., a board-certified general surgery specialist who oversees a medical weight-loss practice in Wellington, Florida, confirms this: "Mounjaro is another brand name with the active ingredient tirzepatide. This injectable prescription medication was FDA-approved in 2022 to improve glycemic control in individuals with type 2 diabetes. Like Zepbound, Mounjaro mimics the GLP-1 and GIP hormones to help regulate blood sugar, improve insulin production, and promote satiety." For patients with type 2 diabetes, Mounjaro offers a powerful tool to manage their condition, working in multiple ways to achieve better blood sugar regulation. Its actions, such as stimulating glucose-dependent insulin release and reducing glucagon production, are directly beneficial for the complex pathology of type 2 diabetes. The approval for Mounjaro emphasizes its role as an adjunct to diet and exercise, reinforcing the importance of lifestyle interventions in diabetes management.

Zepbound: A Dual Approach to Weight and Sleep Apnea

Zepbound's FDA approvals reflect a focus on chronic weight management and related health issues. Its initial approval targeted adults with obesity or those who are overweight with at least one weight-related comorbidity. This broad indication acknowledges the complex nature of obesity as a chronic disease that often contributes to other health problems. The medication is intended to be used in combination with a reduced-calorie diet and increased physical activity, recognizing that medication is most effective when integrated into a comprehensive lifestyle plan. The later approval in 2024 for moderate to severe obstructive sleep apnea in adults with obesity highlights another significant benefit of tirzepatide. Obstructive sleep apnea is a serious condition often linked to excess weight, where breathing repeatedly stops and starts during sleep. By addressing the underlying obesity, Zepbound can directly impact the severity and progression of OSA, offering a new therapeutic option for millions of affected individuals. This dual approval underscores Zepbound's potential to improve not just weight, but also critical weight-related health conditions, thereby enhancing overall patient well-being. The studies for Zepbound, such as the SURMOUNT trials, have shown its strong efficacy in leading to significant weight loss, which is key to its approval for these specific indications.

Understanding the "Why" Behind Different Approvals

The reason for separate FDA approvals, despite the identical active ingredient, often comes down to the specific clinical trials conducted by the pharmaceutical company (Eli Lilly, in this case) and the populations studied. For Mounjaro, the trials specifically measured outcomes related to blood sugar control in people with type 2 diabetes. For Zepbound, the trials, known as the SURMOUNT series, focused on weight loss and improvements in weight-related health markers in people with obesity or overweight. The FDA reviews the data from these trials and grants approval based on the demonstrated safety and efficacy for the specific intended use. This process ensures that medications are prescribed appropriately for the conditions for which they have been rigorously tested and proven effective. While a doctor might observe weight loss in a patient taking Mounjaro for diabetes, or improved blood sugar in a patient taking Zepbound for weight management, the official indications guide prescribing practices and, critically, insurance coverage. The distinct approvals clarify the primary therapeutic goals for each brand name of tirzepatide, helping healthcare providers make informed decisions for their patients.

How Effective Are They for Weight Loss?

Both Mounjaro and Zepbound, containing tirzepatide, have shown impressive effectiveness for weight loss in clinical trials, particularly those focusing on chronic weight management. In the SURMOUNT trials, which specifically investigated tirzepatide for obesity, patients receiving the 15 mg dose experienced an average weight loss of 20.9% of their body weight over a period of 72 weeks. This substantial reduction in weight stands in stark contrast to the placebo group, which only saw an average weight loss of 3.1% during the same timeframe. The data clearly indicates a significant and clinically meaningful impact of tirzepatide on body weight. This level of weight loss is often comparable to or even exceeds that achieved with bariatric surgery in some cases, offering a powerful non-surgical option for individuals struggling with obesity.

Significant and Substantial Weight Loss Achievements

The effectiveness of tirzepatide for weight loss extends beyond just the average percentage. The clinical trial results reveal that a large majority of patients achieved significant weight loss, while a substantial portion achieved even more profound reductions. Specifically, 91% of patients treated with tirzepatide achieved at least 5% body weight loss, which is often considered a clinically significant threshold for improving health outcomes related to obesity. This indicates that almost all individuals who take the medication as prescribed can expect to see meaningful changes in their weight. Furthermore, a remarkable 55% of patients achieved 20% or more body weight loss. Achieving 20% or greater weight loss is often referred to as "substantial" weight loss and is associated with significant improvements in various health parameters, including blood pressure, cholesterol levels, and the risk of developing type 2 diabetes or improving existing conditions. These statistics highlight the consistent and potent weight-reducing effects of tirzepatide across a broad patient population. The SURMOUNT-4 Randomized Clinical Trial further explored the continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity, emphasizing its long-term benefits Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The.

The Role of GIP and GLP-1 in Weight Reduction

The dual action of tirzepatide on both GIP and GLP-1 receptors is central to its exceptional weight loss efficacy. GLP-1 agonists, as a class, are known to help with weight loss by making individuals feel less hungry. They achieve this by slowing down the movement of food through the gastrointestinal tract, which means food stays in the stomach longer, prolonging the feeling of fullness after a meal. This extended satiety makes it easier to eat less and resist overeating. Additionally, GLP-1 signals the brain to indicate fullness, further reducing appetite. Tirzepatide enhances these effects by also activating the GIP receptor. The exact contribution of GIP to weight loss is still an area of active research, but it is understood to complement the GLP-1 pathway. GIP is also an incretin hormone that stimulates insulin secretion and may have direct effects on fat metabolism and energy expenditure. The combined activation of both receptors creates a synergistic effect that results in more pronounced appetite suppression, enhanced satiety, and improved metabolic regulation compared to GLP-1 monotherapy. This comprehensive mechanism of action, which includes slowing gastric emptying, reducing glucagon, improving insulin sensitivity, and directly reducing appetite through central nervous system effects, underpins the impressive weight loss observed in clinical trials. It represents a significant advancement in pharmacological treatments for obesity, moving beyond single-pathway interventions to a more holistic approach to metabolic health. For more details, see WeightWatchers Zepbound vs. Mounjaro.

Comparison to Placebo and Other Interventions

To truly appreciate the effectiveness of tirzepatide, it is essential to compare its results not only to a placebo but also to other available weight loss interventions. The 3.1% weight loss observed in the placebo group over 72 weeks underscores the difficulty of achieving significant and sustained weight loss through diet and exercise alone for many individuals. The difference of nearly 18 percentage points in average weight loss between the active treatment group and the placebo group is statistically and clinically highly significant. When compared to older generations of weight loss medications, tirzepatide's average weight loss of 20.9% is often superior. For example, some GLP-1 receptor agonists used for weight loss typically achieve an average of 10-15% weight loss. This positions tirzepatide as one of the most effective pharmacological treatments currently available for obesity. The magnitude of weight loss seen with tirzepatide can lead to substantial improvements in obesity-related comorbidities, such as type 2 diabetes, hypertension, and dyslipidemia. It also offers a less invasive alternative to bariatric surgery for patients who may not be candidates for surgery or prefer a non-surgical approach. The ongoing research and clinical trials, such as those listed on Lilly's clinical trials website, continue to explore and confirm the broad benefits of tirzepatide Find Lilly Clinical Trials | Learn About Our Research.

What are the Common Side Effects?

When considering any medication, understanding the potential side effects is crucial. For both Zepbound and Mounjaro, which share the same active ingredient, tirzepatide, the common side effects are largely gastrointestinal in nature. These effects are generally mild to moderate and tend to decrease over time as the body adjusts to the medication. The most frequently reported side effects include nausea, affecting 12-22% of patients, and diarrhea, experienced by 12-16% of patients. Vomiting is also a common side effect, reported by 6-13% of patients, along with constipation, which occurs in 6-9% of individuals. Many patients also report stomach pain, affecting 8-11%, and a decreased appetite, experienced by 5-11% of patients. These symptoms are often linked to the medication's mechanism of action, particularly its effect on slowing gastric emptying. While these side effects can be uncomfortable, they are usually manageable with simple strategies and guidance from a healthcare provider.

Strategies for Managing Gastrointestinal Side Effects

Managing the common gastrointestinal side effects associated with tirzepatide is key to ensuring patient comfort and adherence to treatment. Healthcare providers often recommend several practical strategies to help alleviate these symptoms. One effective approach is to eat small, frequent meals throughout the day instead of large, heavy ones. This can reduce the burden on the digestive system and help prevent feelings of fullness that might trigger nausea or discomfort. Avoiding high-fat and greasy foods is another important recommendation, as these types of foods can further slow gastric emptying and exacerbate nausea and stomach pain. Instead, opting for bland, easily digestible foods can be beneficial.

Staying well-hydrated is also critical, especially if experiencing diarrhea or vomiting, to prevent dehydration. Drinking plenty of water or clear liquids can help maintain fluid balance. Some patients find that taking the medication with food can help reduce nausea, although this should be discussed with a doctor, as individual responses may vary. For more persistent or severe nausea, healthcare providers may consider prescribing anti-nausea medications to provide relief. It is important for patients to communicate openly with their doctor about any side effects they experience, as adjustments to the dosing schedule or additional supportive care might be necessary to improve tolerance and ensure a positive treatment experience. Careful titration of the dose, starting low and increasing gradually, also plays a significant role in minimizing the onset and severity of these common side effects.

Understanding Decreased Appetite

While "decreased appetite" is listed as a side effect, affecting 5-11% of patients, it is often a desired therapeutic effect when tirzepatide is used for weight management. The medication's ability to reduce appetite through central nervous system effects and increased satiety is a primary mechanism by which it promotes weight loss. For individuals taking Zepbound for chronic weight management, this decreased appetite is a beneficial outcome, making it easier to adhere to a reduced-calorie diet. However, for some individuals, particularly those who are already struggling with adequate nutritional intake or those who find the appetite suppression too intense, it can be perceived as an adverse effect.

It is important for patients to monitor their food intake and ensure they are still consuming enough nutrients, even with a reduced appetite. Working with a dietitian or healthcare provider can help ensure that dietary choices remain balanced and provide essential vitamins and minerals despite eating less. For patients using Mounjaro primarily for type 2 diabetes, a decreased appetite leading to weight loss is often a welcome secondary benefit, as weight management is crucial for diabetes control. However, any unintended or excessive weight loss should always be discussed with a healthcare professional to ensure it is occurring safely and appropriately. The overall goal is to achieve the therapeutic benefits of tirzepatide while managing any uncomfortable side effects effectively.

Are There Serious Side Effects and Contraindications?

Yes, like all potent medications, tirzepatide (found in both Zepbound and Mounjaro) carries the risk of serious side effects and has specific contraindications that must be carefully considered before starting treatment. The most significant and serious warning is a "black box warning" regarding the risk of thyroid C-cell tumors. This warning is based on studies in rodents, where tirzepatide caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known if tirzepatide causes these tumors, including MTC, in humans. Due to this potential risk, both medications are strictly contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that predisposes individuals to certain types of tumors, including MTC.

Other Serious Risks and When to Seek Medical Attention

Beyond the thyroid tumor warning, there are several other serious side effects associated with tirzepatide. Acute pancreatitis, an inflammation of the pancreas, is a known risk. Symptoms of acute pancreatitis include severe abdominal pain that may radiate to the back, often accompanied by vomiting. Acute gallbladder disease, including gallstones, can also occur. This might present as severe pain in the upper right abdomen, nausea, vomiting, or fever. Patients with type 2 diabetes who are taking Mounjaro should also be aware of potential diabetic retinopathy complications, where existing eye problems related to diabetes could worsen. Additionally, acute kidney injury is a possible serious side effect, especially in patients who experience severe vomiting or diarrhea, leading to dehydration.

It is crucial for patients to be aware of the signs of these serious conditions and to seek immediate medical attention if they experience them. For instance, severe abdominal pain that does not go away, particularly if it radiates to the back, warrants urgent medical evaluation for pancreatitis. Persistent vomiting that prevents fluid intake is also a cause for immediate concern due to the risk of dehydration and kidney injury. Symptoms of thyroid tumors, such as a lump in the neck, hoarseness, or difficulty swallowing, should be reported to a doctor right away. Furthermore, any signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat, difficulty breathing, or a severe rash, require emergency medical attention. These are critical safety considerations that underscore the importance of ongoing monitoring and prompt communication with healthcare providers during treatment with tirzepatide.

Contraindications and Important Safety Information

In addition to the specific contraindications related to thyroid cancer risk and MEN 2, there are other important safety considerations for tirzepatide. Mounjaro is not recommended for individuals with type 1 diabetes. This is because Mounjaro works by stimulating insulin release in a glucose-dependent manner, which is not the primary physiological issue in type 1 diabetes, where the body produces little to no insulin. While both medications are generally suitable for adults, their use in specific populations like pregnant or breastfeeding individuals has not been fully established, and caution is advised.

Healthcare providers should exercise caution when prescribing tirzepatide to patients with a history of pancreatitis, as the medication may increase the risk of recurrence. Regular monitoring is highly recommended during treatment to identify and manage potential serious side effects promptly. This monitoring might include blood tests to check kidney function, liver enzymes, and overall metabolic health. Patients should also be advised about the importance of adhering to their prescribed dosing schedule and not discontinuing the medication without consulting their doctor, as this could lead to a return of symptoms or other adverse effects. Understanding these contraindications and safety guidelines is paramount for safe and effective use of tirzepatide, ensuring that the benefits of the medication outweigh the potential risks for each individual patient. For more details, see NEJM Tirzepatide Obesity Study.

How Do Insurance Coverage and Costs Compare?

The landscape of insurance coverage for Mounjaro and Zepbound can be quite different, primarily because of their distinct FDA approvals. This difference often dictates patient access and out-of-pocket costs, making it a critical factor in treatment decisions. Typically, Mounjaro, being FDA-approved for type 2 diabetes, is more likely to be covered under insurance plans that include diabetes benefits. Many health insurance policies recognize type 2 diabetes as a chronic medical condition requiring ongoing treatment, and therefore, medications like Mounjaro are often included in their formularies, sometimes with a prior authorization requirement. The emphasis here is on the diagnosis of type 2 diabetes, which makes the medication a necessary treatment for blood sugar control.

Zepbound, on the other hand, faces a more complex path to insurance coverage. Its approval for chronic weight management means it falls into a category that many insurance plans have historically viewed as elective or cosmetic, rather than medically necessary, despite the growing recognition of obesity as a chronic disease. While some insurance plans now offer weight management benefits, these often come with stricter criteria, higher co-pays, or may require patients to participate in supervised weight loss programs before coverage is granted. In 2024, Zepbound's additional approval for moderate to severe obstructive sleep apnea in adults with obesity may open new avenues for coverage, as sleep apnea is a recognized medical condition. However, even with this, patients may still face significant hurdles or require extensive documentation to prove medical necessity for weight-related indications.

Impact of Diagnosis on Coverage

The specific diagnosis of a patient plays a pivotal role in determining which medication is prescribed and how readily it will be covered by insurance. If a patient has a confirmed diagnosis of type 2 diabetes, Mounjaro is generally the more straightforward option for coverage. Insurance providers view this as treating a primary disease. For example, if a patient has type 2 diabetes and also struggles with obesity, Mounjaro might be covered for the diabetes, and the weight loss would be a beneficial secondary effect.

Conversely, if a patient's primary diagnosis is obesity (BMI ≥30 kg/m²) or overweight with comorbidities (BMI ≥27 kg/m² with conditions like high blood pressure or dyslipidemia), Zepbound is the appropriate medication according to FDA approvals. However, securing insurance coverage for Zepbound under these circumstances can be challenging. Many plans require a detailed history of failed weight loss attempts through diet and exercise, or documentation of specific weight-related health conditions. The decision to prescribe Mounjaro or Zepbound, therefore, is not solely based on the active ingredient, but critically on the patient's primary medical diagnosis and the specific treatment goals. This distinction often means that while the medications are chemically identical, their accessibility and affordability can vary wildly for individual patients based on their health profile and insurance plan.

Navigating Out-of-Pocket Costs and Patient Assistance Programs

For patients whose insurance does not fully cover Zepbound, or for those with high deductibles or co-pays, the out-of-pocket costs can be substantial. The list price for these medications can be quite high, often exceeding $1,000 per month without insurance. This financial burden can be a significant barrier to access, even for patients who would benefit greatly from the treatment. To help mitigate these costs, pharmaceutical companies like Eli Lilly, the manufacturer of both Mounjaro and Zepbound, often offer patient assistance programs or savings cards. These programs can help eligible patients reduce their out-of-pocket expenses, sometimes significantly, for a certain period. However, eligibility criteria for these programs can vary and may depend on income levels, insurance status, and whether the patient has commercial insurance.

Patients are often advised to investigate their specific insurance plan's formulary and coverage policies for both Mounjaro and Zepbound before starting treatment. This typically involves contacting their insurance provider directly to inquire about coverage, prior authorization requirements, and estimated co-pays. Healthcare providers and their administrative staff often assist patients in navigating these complex insurance landscapes, helping to submit necessary documentation for prior authorization or guiding them toward patient assistance programs. Ultimately, while the clinical efficacy of tirzepatide is well-established, the practical realities of insurance coverage and cost remain a significant consideration for patients and providers alike, influencing prescribing decisions and long-term treatment adherence.

Frequently Asked Questions

What is the main difference between Zepbound and Mounjaro?

The main difference between Zepbound and Mounjaro lies in their FDA-approved uses. Both medications contain the same active ingredient, tirzepatide. Mounjaro is approved for adults with type 2 diabetes to improve blood sugar control alongside diet and exercise. Zepbound is approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. This distinction impacts insurance coverage and prescribing guidelines, even though the medication itself works identically in the body.

Do Zepbound and Mounjaro have the same active ingredient?

Yes, Zepbound and Mounjaro both have the exact same active ingredient: tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This means they work by mimicking two natural gut hormones to manage blood sugar, slow digestion, reduce appetite, and improve insulin sensitivity. Because they share the same active ingredient, their mechanism of action and potential side effects are very similar.

Can Zepbound be used for diabetes?

While Zepbound can lead to improvements in blood sugar control and weight loss, it is not FDA-approved specifically for the treatment of type 2 diabetes. Its primary indication is for chronic weight management in adults with obesity or those who are overweight with comorbidities, and for obstructive sleep apnea. However, because its active ingredient, tirzepatide, also effectively manages blood sugar, patients taking Zepbound for weight loss may experience improved glycemic control as a beneficial secondary effect. For a direct diabetes indication, Mounjaro is the FDA-approved option.

Can Mounjaro be used for weight loss?

Yes, Mounjaro often leads to significant weight loss as a beneficial side effect, even though it is FDA-approved specifically for type 2 diabetes. In clinical trials, tirzepatide at a 15 mg dose resulted in an average weight loss of 20.9% of body weight over 72 weeks. This is because tirzepatide's mechanism of action, which includes reducing appetite and slowing gastric emptying, effectively promotes weight reduction. Many patients with type 2 diabetes who are prescribed Mounjaro experience substantial weight loss, which further aids in managing their diabetes and overall health.

Are there any generic versions available for Zepbound or Mounjaro?

No, neither Zepbound nor Mounjaro currently have generic versions available. Both are brand-name medications manufactured by Eli Lilly and Company. Generic medications typically become available after a patent expires, which can take many years from the time of initial FDA approval. Therefore, for the foreseeable future, patients will only have access to the brand-name versions of tirzepatide under the names Mounjaro and Zepbound.